AAPL348.91+5.08 (+1.48%) ▲|ABBV290.79+4.80 (+1.68%) ▲|ABT104.57+1.93 (+1.88%) ▲|ACN247.22+3.82 (+1.57%) ▲|ADBE248.12-1.64 (-0.66%) ▼|AMAT421.66+5.66 (+1.36%) ▲|AMD566.42-12.02 (-2.08%) ▼|AMGN460.73+8.90 (+1.97%) ▲|AMT185.88+2.13 (+1.16%) ▲|AMZN243.79-10.81 (-4.25%) ▼|AVGO345.00-6.81 (-1.94%) ▼|AXP323.71+5.77 (+1.81%) ▲|BA172.65+5.51 (+3.30%) ▲|BAC51.14+0.29 (+0.57%) ▲|BKNG150.43+2.49 (+1.68%) ▲|BLK1,176.24+18.36 (+1.59%) ▲|BMY61.39+0.82 (+1.35%) ▲|BNY149.37+0.78 (+0.52%) ▲|BRK-B541.96+1.62 (+0.30%) ▲|C125.76+1.65 (+1.33%) ▲|CAT647.39-65.99 (-9.25%) ▼|CL93.16+1.47 (+1.60%) ▲|CMCSA22.27+0.70 (+3.25%) ▲|COF208.74+3.86 (+1.88%) ▲|COP150.03+0.97 (+0.65%) ▲|COST996.08+13.35 (+1.36%) ▲|CRM230.90-11.21 (-4.63%) ▼|CSCO108.59-1.70 (-1.54%) ▼|CVS90.33+0.38 (+0.42%) ▲|CVX231.46+2.26 (+0.99%) ▲|DE660.00+19.33 (+3.02%) ▲|DHR236.98+2.91 (+1.24%) ▲|DIS110.91+1.87 (+1.72%) ▲|DUK125.90+2.33 (+1.89%) ▲|EMR170.74+3.03 (+1.81%) ▲|FDX307.82+3.24 (+1.06%) ▲|GD370.82+16.47 (+4.65%) ▲|GE313.05+11.92 (+3.96%) ▲|GEV887.85+9.82 (+1.12%) ▲|GILD165.61+6.41 (+4.03%) ▲|GM85.72+3.24 (+3.93%) ▲|GOOG282.32-39.57 (-12.29%) ▼|GOOGL283.82-41.07 (-12.64%) ▼|GS927.73+2.56 (+0.28%) ▲|HD328.98+11.42 (+3.60%) ▲|HON222.14+2.88 (+1.31%) ▲|IBM258.28+5.06 (+2.00%) ▲|INTC92.07-3.46 (-3.62%) ▼|INTU331.19+3.00 (+0.91%) ▲|ISRG448.76+4.58 (+1.03%) ▲|JNJ275.20+4.16 (+1.53%) ▲|JPM343.58+4.28 (+1.26%) ▲|KO92.82+1.09 (+1.19%) ▲|LIN503.15-5.01 (-0.99%) ▼|LLY1,373.70+85.40 (+6.63%) ▲|LMT643.59+13.84 (+2.20%) ▲|LOW207.28+8.88 (+4.48%) ▲|LRCX254.39+0.57 (+0.22%) ▲|MA635.70+25.39 (+4.16%) ▲|MCD257.38+6.88 (+2.75%) ▲|MDLZ62.53+0.66 (+1.07%) ▲|MDT97.11+2.33 (+2.46%) ▲|META624.52+12.03 (+1.96%) ▲|MMM177.36+4.56 (+2.64%) ▲|MO76.75+3.76 (+5.15%) ▲|MRK146.33+5.40 (+3.83%) ▲|MS190.00-0.13 (-0.07%) ▼|MSFT530.14-0.87 (-0.16%) ▼|MU934.27-48.96 (-4.98%) ▼|NEE82.14+1.12 (+1.38%) ▲|NFLX62.05+0.06 (+0.10%) ▲|NKE38.42+1.27 (+3.42%) ▲|NOW109.67-40.46 (-26.95%) ▼|NVDA213.66-1.72 (-0.80%) ▼|ORCL139.56-4.98 (-3.45%) ▼|PEP133.79+1.16 (+0.87%) ▲|PFE29.95+0.50 (+1.70%) ▲|PG160.59+2.33 (+1.47%) ▲|PLTR196.42-0.39 (-0.20%) ▼|PM208.50+5.86 (+2.89%) ▲|QCOM185.41+2.44 (+1.33%) ▲|RTX199.40+3.56 (+1.82%) ▲|SBUX105.51+2.31 (+2.24%) ▲|SCHW89.47+0.71 (+0.80%) ▲|SO92.99+1.47 (+1.61%) ▲|SPG215.72+4.48 (+2.12%) ▲|T20.92+0.22 (+1.06%) ▲|TMO709.18+5.03 (+0.71%) ▲|TMUS147.29-0.79 (-0.53%) ▼|TSLA403.30-0.92 (-0.23%) ▼|TXN312.94+3.11 (+1.00%) ▲|UBER65.74+0.47 (+0.72%) ▲|UNH410.91+3.81 (+0.94%) ▲|UNP301.93+4.13 (+1.39%) ▲|UPS107.33+1.71 (+1.62%) ▲|USB60.64+1.04 (+1.75%) ▲|V410.54+9.94 (+2.48%) ▲|VZ43.66+0.48 (+1.11%) ▲|WFC84.81+1.14 (+1.36%) ▲|WMT121.25+2.48 (+2.09%) ▲|XOM183.29+1.27 (+0.70%) ▲|AAPL348.91+5.08 (+1.48%) ▲|ABBV290.79+4.80 (+1.68%) ▲|ABT104.57+1.93 (+1.88%) ▲|ACN247.22+3.82 (+1.57%) ▲|ADBE248.12-1.64 (-0.66%) ▼|AMAT421.66+5.66 (+1.36%) ▲|AMD566.42-12.02 (-2.08%) ▼|AMGN460.73+8.90 (+1.97%) ▲|AMT185.88+2.13 (+1.16%) ▲|AMZN243.79-10.81 (-4.25%) ▼|AVGO345.00-6.81 (-1.94%) ▼|AXP323.71+5.77 (+1.81%) ▲|BA172.65+5.51 (+3.30%) ▲|BAC51.14+0.29 (+0.57%) ▲|BKNG150.43+2.49 (+1.68%) ▲|BLK1,176.24+18.36 (+1.59%) ▲|BMY61.39+0.82 (+1.35%) ▲|BNY149.37+0.78 (+0.52%) ▲|BRK-B541.96+1.62 (+0.30%) ▲|C125.76+1.65 (+1.33%) ▲|CAT647.39-65.99 (-9.25%) ▼|CL93.16+1.47 (+1.60%) ▲|CMCSA22.27+0.70 (+3.25%) ▲|COF208.74+3.86 (+1.88%) ▲|COP150.03+0.97 (+0.65%) ▲|COST996.08+13.35 (+1.36%) ▲|CRM230.90-11.21 (-4.63%) ▼|CSCO108.59-1.70 (-1.54%) ▼|CVS90.33+0.38 (+0.42%) ▲|CVX231.46+2.26 (+0.99%) ▲|DE660.00+19.33 (+3.02%) ▲|DHR236.98+2.91 (+1.24%) ▲|DIS110.91+1.87 (+1.72%) ▲|DUK125.90+2.33 (+1.89%) ▲|EMR170.74+3.03 (+1.81%) ▲|FDX307.82+3.24 (+1.06%) ▲|GD370.82+16.47 (+4.65%) ▲|GE313.05+11.92 (+3.96%) ▲|GEV887.85+9.82 (+1.12%) ▲|GILD165.61+6.41 (+4.03%) ▲|GM85.72+3.24 (+3.93%) ▲|GOOG282.32-39.57 (-12.29%) ▼|GOOGL283.82-41.07 (-12.64%) ▼|GS927.73+2.56 (+0.28%) ▲|HD328.98+11.42 (+3.60%) ▲|HON222.14+2.88 (+1.31%) ▲|IBM258.28+5.06 (+2.00%) ▲|INTC92.07-3.46 (-3.62%) ▼|INTU331.19+3.00 (+0.91%) ▲|ISRG448.76+4.58 (+1.03%) ▲|JNJ275.20+4.16 (+1.53%) ▲|JPM343.58+4.28 (+1.26%) ▲|KO92.82+1.09 (+1.19%) ▲|LIN503.15-5.01 (-0.99%) ▼|LLY1,373.70+85.40 (+6.63%) ▲|LMT643.59+13.84 (+2.20%) ▲|LOW207.28+8.88 (+4.48%) ▲|LRCX254.39+0.57 (+0.22%) ▲|MA635.70+25.39 (+4.16%) ▲|MCD257.38+6.88 (+2.75%) ▲|MDLZ62.53+0.66 (+1.07%) ▲|MDT97.11+2.33 (+2.46%) ▲|META624.52+12.03 (+1.96%) ▲|MMM177.36+4.56 (+2.64%) ▲|MO76.75+3.76 (+5.15%) ▲|MRK146.33+5.40 (+3.83%) ▲|MS190.00-0.13 (-0.07%) ▼|MSFT530.14-0.87 (-0.16%) ▼|MU934.27-48.96 (-4.98%) ▼|NEE82.14+1.12 (+1.38%) ▲|NFLX62.05+0.06 (+0.10%) ▲|NKE38.42+1.27 (+3.42%) ▲|NOW109.67-40.46 (-26.95%) ▼|NVDA213.66-1.72 (-0.80%) ▼|ORCL139.56-4.98 (-3.45%) ▼|PEP133.79+1.16 (+0.87%) ▲|PFE29.95+0.50 (+1.70%) ▲|PG160.59+2.33 (+1.47%) ▲|PLTR196.42-0.39 (-0.20%) ▼|PM208.50+5.86 (+2.89%) ▲|QCOM185.41+2.44 (+1.33%) ▲|RTX199.40+3.56 (+1.82%) ▲|SBUX105.51+2.31 (+2.24%) ▲|SCHW89.47+0.71 (+0.80%) ▲|SO92.99+1.47 (+1.61%) ▲|SPG215.72+4.48 (+2.12%) ▲|T20.92+0.22 (+1.06%) ▲|TMO709.18+5.03 (+0.71%) ▲|TMUS147.29-0.79 (-0.53%) ▼|TSLA403.30-0.92 (-0.23%) ▼|TXN312.94+3.11 (+1.00%) ▲|UBER65.74+0.47 (+0.72%) ▲|UNH410.91+3.81 (+0.94%) ▲|UNP301.93+4.13 (+1.39%) ▲|UPS107.33+1.71 (+1.62%) ▲|USB60.64+1.04 (+1.75%) ▲|V410.54+9.94 (+2.48%) ▲|VZ43.66+0.48 (+1.11%) ▲|WFC84.81+1.14 (+1.36%) ▲|WMT121.25+2.48 (+2.09%) ▲|XOM183.29+1.27 (+0.70%) ▲|
18.1 C
New York
Thursday, October 29, 2026

Tag: communication

Global Dry Film Photoresist Market Set for Robust Growth with Expanding Semiconductor Ecosystem | Valuates Reports

Dry Film Photoresist Market is Segmented by Type (Positive Dry Film Photoresist, Negative Dry Film Photoresist), by Application (PCB, Semiconductor Packaging, Others): Global Opportunity...

Questex’s Fierce Pharma Unveils Powerhouse Conference Program for the Inaugural Fierce Pharma Week, Where Pharma’s Future Takes Shape

Unites Pharma Marketing, PR & Communications, New Product Planning & Commercialization, and Medical Affairs Communities; Thought Leaders from AbbVie, AstraZeneca, BMS, GSK, Johnson & Johnson, NBCUniversal, Pfizer, Takeda and More Deliver Unparalleled Education

Redefining Urban Mobility: NAVEE’s V1 Pro Steals the Spotlight at Micromobility Europe

BRUSSELS, June 23, 2025 /PRNewswire/ -- Brussels Expo, June 17–18, 2025 – At Micromobility Europe (MME), the world's leading conference for small electric vehicles, NAVEE...

Verizon announces final results of its private exchange offers for 10 series of notes and related tender offers open to certain investors

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Verizon Communications Inc. (“Verizon”) (NYSE, Nasdaq: VZ) today announced the final results of its Exchange Offers (as defined below) and its Cash Offers (as defined below).

UScellular Breaks GUINNESS WORLD RECORDS™ Title for Longest Temporary Mini Golf Hole

Company built a 507-foot mini golf hole in Des Moines, Iowa to provide people a fun activity away from their phones DES MOINES, Iowa, June...

Aetna Supports Industry Actions to Simplify Prior Authorization

Company commits to distinctive actions that will make it easier to navigate the health care system, access care, and achieve better healthHARTFORD, Conn., June...

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

Navamedic ASA expands into addiction treatment through the acquisition of the business of dne pharma and announces a partially underwritten rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE...

AI Query Processing: Quantifying Carbon Footprint in Algorithmic Models

Artificial intelligence, particularly generative AI, is becoming integral to various aspects of daily life, from search engine optimization to automated email composition. However, the...

Indonesian DPR Immerses in Shenzhen’s Cutting-Edge Tech during SZMG’s “Telling China’s Story” Event, Calls for Deeper China-Indonesia Cooperation.

SHENZHEN, China, June 23, 2025 /PRNewswire/ -- This year marks the 75th anniversary of the establishment of diplomatic relations between China and Indonesia. Telling...

Cyberway Product Innovation Platform: Empowering Enterprise Innovation Processes and Building Exceptional Product Strength

GUANGZHOU , June 22, 2025 /PRNewswire/ -- In the fiercely competitive FMCG market, only efficient innovation can create a true competitive edge. As consumer preferences...

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. ("PepGen" or the "Company")...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCommunication